Premium
Driving Under the Influence of Synthetic Cannabinoid Receptor Agonist XLR ‐11
Author(s) -
Lemos Nikolas P.
Publication year - 2014
Publication title -
journal of forensic sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.715
H-Index - 96
eISSN - 1556-4029
pISSN - 0022-1198
DOI - 10.1111/1556-4029.12550
Subject(s) - synthetic cannabinoids , cannabinoid , agonist , cannabinoid receptor , cannabinoid receptor agonists , rimonabant , inverse agonist , pharmacology , driving under the influence , chemistry , medicine , poison control , receptor , emergency medicine , injury prevention
The case of a 22‐year‐old male Caucasian driver is presented. He was involved in a traffic collision. At the roadside, he displayed blank stare and mellow speech with a barely audible voice. A DRE found low body temperature, rigid muscle tone, normal pulse, lack of horizontal and vertical gaze nystagmus, nonconvergence of the eyes, dilated pupil size, and normal Pupillary reaction to light. A standard toxicology DUID protocol was performed on the driver's whole blood including ELISA and GC ‐ MS drug screens with negative results. Additional drug screening was undertaken for bath salts and synthetic cannabinoid receptor agonists by LC ‐ MS / MS by a commercial laboratory and identified the synthetic cannabinoid receptor agonist XLR ‐11 in the driver's blood. XLR ‐11 was subsequently quantified at 1.34 ng/mL. This is the first documented case involving a driver operating a motor vehicle under the influence of the synthetic cannabinoid receptor agonist XLR ‐11.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom